Semaglutide 10mg

Chemical Information:

• Molecular Formula: C₁₈₇H₂₉₁N₄₅O₅₉
• Molecular Weight: 4113.58 g/mol
• Sequence: HA¹EGTFTSDVSSYLEGQAAKEFIAWLVKGRG (modified with an octanoic acid side chain at lysine position)
• Molecular Structure: Refer to Certificate of Analysis for detailed structural information.

Description:
Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1 (GLP-1), specifically designed for prolonged stability and enhanced bioactivity within research contexts. Extensively investigated in laboratory studies, Semaglutide provides researchers with a tool to examine complex metabolic pathways, including glucose regulation, appetite control, and lipid homeostasis. This peptide is supplied as a lyophilized powder, ensuring optimal stability for advanced metabolic research applications.

Research Applications:
Semaglutide is actively studied for potential roles in:

• Glucose Regulation: Investigating insulin secretion dynamics, glucose metabolism, and related signaling pathways.
• Weight and Appetite Modulation: Evaluating its influence on energy balance, hunger signals, and body composition.
• Cardiovascular Health Studies: Exploring cardiovascular risk modulation associated with metabolic dysfunction in experimental settings.
• Liver Health Research: Assessing potential impacts on non-alcoholic fatty liver disease (NAFLD) and hepatic metabolism.

Storage and Handling:

• Store lyophilized powder at -20°C.
• After reconstitution, refrigerate at 2-8°C and use promptly.
• Maintain aseptic handling practices to ensure sterility and product integrity.

Product Specifications:

• Purity: ≥99% (HPLC Verified)
• Appearance: Lyophilized white powder
• Solubility: Soluble in bacteriostatic water

Important Note:
This product is strictly FOR RESEARCH USE ONLY and is intended exclusively for in vitro research and laboratory experimentation by qualified professionals. It is not a drug, food, cosmetic, or dietary supplement, and has not been evaluated by the FDA. This peptide is not intended to diagnose, treat, cure, or prevent any disease. The bodily introduction into humans or animals is strictly prohibited by law. Any misuse, misbranding, or mislabeling is a violation of federal regulations and may result in legal action under applicable federal, state, or local laws.

References:
Referenced scientific publications include:

• Marso, S. P., et al. (2016). “Semaglutide and Cardiovascular Outcomes in Type 2 Diabetes.” New England Journal of Medicine.
• Wilding, J. P. H., et al. (2021). “Semaglutide for Weight Management in Adults with Obesity.” Lancet Diabetes & Endocrinology.